...
首页> 外文期刊>Journal of the International Aids Society >HIV programmatic outcomes following implementation of the ‘Treat‐All’ policy in a public sector setting in Eswatini: a prospective cohort study
【24h】

HIV programmatic outcomes following implementation of the ‘Treat‐All’ policy in a public sector setting in Eswatini: a prospective cohort study

机译:艾滋病毒计划在埃斯瓦蒂尼在公共部门环境中实施“对待 - 所有”政策后:一项潜在的队列研究

获取原文
           

摘要

Introduction The Treat‐All policy – antiretroviral therapy (ART) initiation irrespective of CD4 cell criteria – increases access to treatment. Many ART programmes, however, reported increasing attrition and viral failure during treatment expansion, questioning the programmatic feasibility of Treat‐All in resource‐limited settings. We aimed to describe and compare programmatic outcomes between Treat‐All and standard of care (SOC) in the public sectors of Eswatini. Methods This is a prospective cohort study of ≥16‐year‐old HIV‐positive patients initiated on first‐line ART under Treat‐All and SOC in 18 health facilities of the Shiselweni region, from October 2014 to March 2016. SOC followed the CD4 350 and 500?cells/mmsup3/sup treatment eligibility thresholds. Kaplan‐Meier estimates were used to describe crude programmatic outcomes. Multivariate flexible parametric survival models were built to assess associations of time from ART initiation with the composite unfavourable outcome of all‐cause attrition and viral failure. Results Of the 3170 patients, 1888 (59.6%) initiated ART under Treat‐All at a median CD4 cell count of 329 (IQR 168 to 488) cells/mmsup3/sup compared with 292 (IQR 161 to 430) ( p ?0.001) under SOC. Although crude programme retention at 36?months tended to be lower under Treat‐All (71%) than SOC (75%) ( p =?0.002), it was similar in covariate‐adjusted analysis (adjusted hazard ratio [aHR] 1.06, 95% CI 0.91 to 1.23). The hazard of viral suppression was higher for Treat‐All (aHR 1.12, 95% CI 1.01 to 1.23), while the hazard of viral failure was comparable (Treat‐All: aHR 0.89, 95% CI 0.53 to 1.49). Among patients with advanced HIV disease (n?=?1080), those under Treat‐All (aHR 1.13, 95% CI 0.88 to 1.44) had a similar risk of an composite unfavourable outcome to SOC. Factors increasing the risk of the composite unfavourable outcome under both interventions were aged 16 to 24?years, being unmarried, anaemia, ART initiation on the same day as HIV care enrolment and CD4?≤?100?cells/mmsup3/sup. Under Treat‐All only, the risk of the unfavourable outcome was higher for pregnant women, WHO III/IV clinical stage and elevated creatinine. Conclusions Compared to SOC, Treat‐All resulted in comparable retention, improved viral suppression and comparable composite outcomes of retention without viral failure.
机译:引言 - 所有政策 - 抗逆转录病毒治疗(ART)引发与CD4细胞标准无关 - 增加对治疗的途径。然而,许多艺术计划报告了治疗扩展过程中的磨损和病毒失败,质疑待遇的程序性可行性 - 所有在资源限制的环境中。我们的旨在描述和比较埃斯瓦蒂尼公共部门的治疗和护理标准(SoC)之间的编程结果。方法这是一项前瞻性队列研究,≥16岁的艾滋病毒阳性患者≥18岁至2016年10月的18个卫生设施的一线艺术作品,在谢谢列兹地区的18个卫生设施。SoC跟随CD4 350和500?细胞/ mm 3 处理资格阈值。 Kaplan-Meier估计用于描述粗略的程序化结果。建立了多变量柔性参数生存模型,以评估从艺术启动的时间的关联,与所有导致磨损和病毒失败的复合不利的结果。 3170例患者的结果,1888名(59.6%)在治疗中引发的艺术 - 全部在329(IQR 168至488)细胞/ mm 3 与292(IQR 161至430相比soc下的)(p <0.001)。虽然粗略计划保留在36?月份往往较低的治疗(71%)比SoC(75%)(P = 0.002),但在调节的分析中相似(调整后危险比[AHR] 1.06, 95%CI 0.91至1.23)。治疗含量(AHR 1.12,95%CI 1.01至1.23)的病毒抑制的危害较高,而病毒衰竭的危害是可比的(治疗 - 所有:AHR 0.89,95%CI 0.53至1.49)。在高级艾滋病毒疾病(N?= 1080)中,患者的治疗 - 所有(AHR 1.13,95%CI 0.88至1.44)对SoC的复合性不利结果的风险相似。增加因其两种干预措施的综合不利结果风险的因素年龄为16至24岁,是未婚,贫血,在同一天的贫血,作为艾滋病毒护理入学和CD4?≤α100?细胞/ mm 3 < / sup>。根据对待 - 所有人,孕妇患有不利结果的风险较高,III / IV临床阶段和肌酐升高。结论与SoC相比,治疗 - 所有导致相当的保留,改善病毒抑制和饲养的可比复合结果而没有病毒失败。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号